ClinicalTrials.gg
CompletedNCT00963105Updated Oct 31, 2018Results posted

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

A Phase 2 interventional study of lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia, sponsored by Celgene. Completed at 52 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-31.

Primary conditionLeukemia, Lymphocytic, Chronic, B-CellRegistry: RecurrenceReclassifiedWhy we changed it
Registry
Recurrence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Leukemia, Lymphocytic, Chronic, B-Cell
Why
  1. Recurrence describes something many studies share rather than a condition a study is about.
  2. The study's listed conditions name Leukemia, Lymphocytic, Chronic, B-Cell.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell — 1 open to participants now, 5 under way, none of them phase 3. Lenalidomide · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
6th of 77
104 · median 29
Started
2009
with 9 others
Phase 2
42 of 78
none open now
Registered
30th of 78
by date
Lead sponsor
4 of 78
Celgene

Among the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 6th largest by enrollment of the 77 interventional ones that give a count, is one of 10 that started in 2009, is one of 42 in phase 2, and was the 30th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing lenalidomide in Leukemia, Lymphocytic, Chronic, B-Cell, or all of them as a file.
02

Study summary

The purpose of this study is to determine the safety and effectiveness of different dose regimens of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).

03

Conditions studied

  • Relapsed or Refractory Chronic Lymphocytic Leukemia

Browse trials for

04

In context

Leukemia, Lymphocytic, Chronic, B-Cell Reclassified

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

This study's enrollment of 104 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted before Celgene became part of Bristol-Myers Squibb.

Compared within Leukemia, Lymphocytic, Chronic, B-Cell, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Recurrence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years at the time of signing the form
  • Must be able to adhere to the study visit schedule and other protocol requirements
  • Must have a documented diagnosis of B-cell CLL
  • Must be to at least 1 regimen for treatment of CLL. At least one of the prior treatments must have included a purine analog-based or bendamustine-based regimen
  • Must have an (ECOG) performance status score of ≤ 2.

Exclusion criteria

Exclusion Criteria:

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the form
  • Active infections requiring systemic antibiotics
  • Systemic treatment for B-cell CLL within 28 days of initiation of lenalidomide treatment
  • Alemtuzumab therapy within 120 days of initiating lenalidomide treatment
  • Prior therapy with lenalidomide
  • History of grade 4 rash due to prior thalidomide treatment
  • Planned or allogeneic bone marrow transplantation
  • Central nervous system (CNS) involvement as documented by spinal fluid cytology or imaging.
  • Uncontrolled hyperthyroidism or hypothyroidism
  • Venous thromboembolism within 12 months
  • ≥ Grade 2 neuropathy
  • Uncontrolled hemolytic anemia or thrombocytopenia
  • Disease transformation [i.e. Richter's Syndrome (lymphomas) or prolymphocytic leukemia]
  • Participation in any clinical study or having taken any therapy within 28 days prior to initiating lenalidomide therapy
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Experimental
    Lenalidomide 5 mg

    Participants received a starting dose of 5 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability. Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug

    Drug: lenalidomide

  • Experimental
    Lenalidomide 10 mg

    Participants received a starting dose of 10 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability. Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug

    Drug: lenalidomide

  • Experimental
    Lenalidomide 15 mg

    Participants received a starting dose of 15 mg lenalidomide orally once a day. Lenalidomide dose was escalated by 5 mg in a step-wise manner every 28 days up to a maximum dose of 25 mg daily based on tolerability. Participants continued receiving study drug until disease progression or unacceptable toxicity, unless they withdrew consent or had other reasons to discontinue from study drug

    Drug: lenalidomide

Interventions

  • Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows: * Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily * Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily * Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity

07

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-emergent Adverse Events

    Adverse events (AEs) were graded for severity by the investigator according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 with the exceptions of hematologic toxicities and tumor lysis syndrome, according to the following scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening or disabling AE Grade 5 = Death The investigator determined the relationship of each AE to study drug based on the timing of the AE and whether other medications, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the observed event.

    Time frame: From first dose of study drug to 30 days after the last dose; the maximum duration of treatment was 251, 265, and 267 weeks in the 5 mg, 10 mg, and 15 mg treatment groups respectively.

Secondary outcomes

  1. Overall Response Rate (ORR)

    ORR was defined as the percentage of patients with a complete response (CR), CR with incomplete bone marrow (BM) recovery (CRi) or partial response (PR) during treatment. Response was assessed according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines. Per the guidelines, a CR required peripheral blood lymphocytes below 4 x 10\^9/L, absence of lymphadenopathy, no hepatomegaly or splenomegaly, absence of disease and blood counts neutrophils \>1.5 x 10\^9/L, platelets \>100 x 10\^9/L, hemoglobin (hgb) \>11g/dL) and BM at least normocellular for age. CRi = CR with incomplete BM recovery. PR = required at least 2 months from end of treatment, a ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value and either a ≥ 50% reduction in lymphadenopathy or ≥50% reduction of liver enlargement or ≥50% reduction of spleen enlargement plus neutrophils \>1.5 x 10\^9/ or ≥50% increase, platelets \>100 x 10\^9/L or ≥50% increase, hgb 11 g/dL.

    Time frame: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.

  2. Kaplan-Meier Estimate of Duration of Response

    Duration of response (DOR) was defined as the time from the first visit where PR, CRi, or CR was documented to progressive disease (PD). Duration of response was censored at the last date that the participant was known to be progression-free for participants who had not progressed at the time of analysis or who withdrew consent or were lost to follow-up prior to documentation of progression.

    Time frame: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.

  3. Time to Response

    Time to response (TTR) was calculated as the time from randomization to the first documented date of response (PR, CRi or CR) based on iwCLL guidelines for participants with an objective response during the treatment period.

    Time frame: Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.

  4. Kaplan-Meier Estimate of Time to Progression

    Time to progression (TTP) was defined as the time from randomization to the first documented progression. For participants who did not progress during the study, TTP was censored at the last adequate response assessment showing evidence of no disease progression.

    Time frame: From randomization until the end of the study; maximum time on study was 91 months.

  5. Kaplan-Meier Estimate of Event-Free Survival

    Event-free survival (EFS) is the interval between the start of treatment to the first sign of disease progression, or treatment for relapse or death (whichever occurred first). If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.

    Time frame: From randomization until the end of the study; maximum time on study was 91 months.

  6. Kaplan-Meier Estimate of Progression Free Survival

    Progression-free survival (PFS) was calculated as the time from randomization to the first documented progression or death due to any cause during or after the treatment period, whichever occurred first. The progression date was assigned to the earliest time when any progression is observed without prior missing assessments. If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.

    Time frame: From randomization until the end of the study; maximum time on study was 91 months.

  7. Kaplan-Meier Estimate of Overall Survival

    Overall survival (OS) was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who had withdrawn consent or were lost to follow-up before death was documented.

    Time frame: From randomization until the end of the study; maximum time on study was 91 months.

08

Results

Posted Oct 2, 2018

Participant flow

Participants were randomized at 29 sites from North America and Europe.

Participant flow — Overall Study
MilestoneLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
Started343535
Received treatment343435
Completed343535
Not completed000

Outcome measures

PrimaryNumber of Participants With Treatment-emergent Adverse Events

Adverse events (AEs) were graded for severity by the investigator according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 3.0 with the exceptions of hematologic toxicities and tumor lysis syndrome, according to the following scale: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life Threatening or disabling AE Grade 5 = Death The investigator determined the relationship of each AE to study drug based on the timing of the AE and whether other medications, therapeutic interventions, or underlying conditions could provide a sufficient explanation for the observed event.

Time frame:
From first dose of study drug to 30 days after the last dose; the maximum duration of treatment was 251, 265, and 267 weeks in the 5 mg, 10 mg, and 15 mg treatment groups respectively.
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events
ParticipantsLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
Any adverse events343435
Treatment-related adverse events (TRAE)333432
Grade 3/4 adverse events333234
Treatment-related Grade 3/4 adverse events313230
Grade 5 adverse events443
Treatment-related Grade 5 adverse events220
Serious adverse events242427
Treatment-related serious adverse events151320
AE leading to discontinuation of study drug211716
TRAE leading to discontinuation of study drug161413
AE leading to study drug dose reduction only865
AE leading to study drug dose interruption only252425
AE leading to study drug interruption & reduction182619
SecondaryOverall Response Rate (ORR)

ORR was defined as the percentage of patients with a complete response (CR), CR with incomplete bone marrow (BM) recovery (CRi) or partial response (PR) during treatment. Response was assessed according to the 2008 International Workshop on Chronic Lymphocytic Leukemia (iwCLL) guidelines. Per the guidelines, a CR required peripheral blood lymphocytes below 4 x 10\^9/L, absence of lymphadenopathy, no hepatomegaly or splenomegaly, absence of disease and blood counts neutrophils \>1.5 x 10\^9/L, platelets \>100 x 10\^9/L, hemoglobin (hgb) \>11g/dL) and BM at least normocellular for age. CRi = CR with incomplete BM recovery. PR = required at least 2 months from end of treatment, a ≥50% decrease in peripheral blood lymphocyte count from the pre-treatment value and either a ≥ 50% reduction in lymphadenopathy or ≥50% reduction of liver enlargement or ≥50% reduction of spleen enlargement plus neutrophils \>1.5 x 10\^9/ or ≥50% increase, platelets \>100 x 10\^9/L or ≥50% increase, hgb 11 g/dL.

Time frame:
Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
Overall Response Rate (ORR)47.137.140.0
SecondaryKaplan-Meier Estimate of Duration of Response

Duration of response (DOR) was defined as the time from the first visit where PR, CRi, or CR was documented to progressive disease (PD). Duration of response was censored at the last date that the participant was known to be progression-free for participants who had not progressed at the time of analysis or who withdrew consent or were lost to follow-up prior to documentation of progression.

Time frame:
Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
Reported as:
Median · weeks
Kaplan-Meier Estimate of Duration of Response
weeksLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
Kaplan-Meier Estimate of Duration of Response101.1 (60.6 to 239.3)35.1 (22.0 to NA)88.8 (72.1 to 127.3)
SecondaryTime to Response

Time to response (TTR) was calculated as the time from randomization to the first documented date of response (PR, CRi or CR) based on iwCLL guidelines for participants with an objective response during the treatment period.

Time frame:
Response was assessed after 3 cycles of therapy (Week 12) and every 4 weeks thereafter until disease progression. Maximum time on study was 91 months.
Reported as:
Median · weeks
Time to Response
weeksLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
Time to Response16.9 (12.1 to 74.1)12.6 (8.4 to 52.1)12.7 (12.0 to 147.3)
SecondaryKaplan-Meier Estimate of Time to Progression

Time to progression (TTP) was defined as the time from randomization to the first documented progression. For participants who did not progress during the study, TTP was censored at the last adequate response assessment showing evidence of no disease progression.

Time frame:
From randomization until the end of the study; maximum time on study was 91 months.
Reported as:
Median · weeks
Kaplan-Meier Estimate of Time to Progression
weeksLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
Kaplan-Meier Estimate of Time to Progression96.3 (20.6 to 251.3)47.6 (31.9 to 261.1)66.3 (20.1 to 89.3)
SecondaryKaplan-Meier Estimate of Event-Free Survival

Event-free survival (EFS) is the interval between the start of treatment to the first sign of disease progression, or treatment for relapse or death (whichever occurred first). If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.

Time frame:
From randomization until the end of the study; maximum time on study was 91 months.
Reported as:
Median · weeks
Kaplan-Meier Estimate of Event-Free Survival
weeksLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
Kaplan-Meier Estimate of Event-Free Survival25.6 (16.1 to 77.6)31.9 (21.1 to 47.6)24.1 (13.4 to 66.3)
SecondaryKaplan-Meier Estimate of Progression Free Survival

Progression-free survival (PFS) was calculated as the time from randomization to the first documented progression or death due to any cause during or after the treatment period, whichever occurred first. The progression date was assigned to the earliest time when any progression is observed without prior missing assessments. If withdrawal of consent or loss to follow-up occurred before documented progression or death, then these observations were censored at the date when the last complete tumor assessments determined a lack of progression.

Time frame:
From randomization until the end of the study; maximum time on study was 91 months.
Reported as:
Median · weeks
Kaplan-Meier Estimate of Progression Free Survival
weeksLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
Kaplan-Meier Estimate of Progression Free Survival31.4 (16.1 to 96.3)45.1 (22.4 to 120.1)66.3 (16.1 to 89.3)
SecondaryKaplan-Meier Estimate of Overall Survival

Overall survival (OS) was defined as the time from randomization to death from any cause. Overall survival was censored at the last date that the participant was known to be alive for participants who were alive at the time of analysis and for participants who had withdrawn consent or were lost to follow-up before death was documented.

Time frame:
From randomization until the end of the study; maximum time on study was 91 months.
Reported as:
Median · weeks
Kaplan-Meier Estimate of Overall Survival
weeksLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
Kaplan-Meier Estimate of Overall Survival161.0 (64.9 to 209.0)106.7 (83.4 to 235.7)154.6 (80.9 to 214.7)

Adverse events

Collected over From first dose of study drug to 30 days after the last dose; the maximum duration of treatment was 251, 265, and 267 weeks in the 5 mg, 10 mg, and 15 mg treatment groups respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenalidomide 5 mg24/34 (70.6%)24/34 (70.6%)34/34 (100%)
Lenalidomide 10 mg23/34 (67.6%)24/34 (70.6%)34/34 (100%)
Lenalidomide 15 mg26/35 (74.3%)27/35 (77.1%)35/35 (100%)
Most frequent serious events
Showing 10 of 115
Most frequent serious events
EventLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
PNEUMONIAInfections and infestations5/344/3410/35
TUMOUR FLARENeoplasms benign, malignant and unspecified (incl cysts and polyps)2/340/346/35
FEBRILE NEUTROPENIABlood and lymphatic system disorders2/344/344/35
ABDOMINAL PAINGastrointestinal disorders0/343/340/35
HYPERCALCAEMIAMetabolism and nutrition disorders3/340/342/35
NEUTROPENIABlood and lymphatic system disorders1/342/343/35
PYREXIAGeneral disorders2/341/342/35
BACTERAEMIAInfections and infestations2/340/340/35
PNEUMOCYSTIS JIROVECII PNEUMONIAInfections and infestations0/342/340/35
SQUAMOUS CELL CARCINOMA OF SKINNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/341/341/35
Most frequent other events
Showing 10 of 139
Most frequent other events
EventLenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mg
NEUTROPENIABlood and lymphatic system disorders25/3430/3426/35
THROMBOCYTOPENIABlood and lymphatic system disorders17/3425/3421/35
FATIGUEGeneral disorders18/3417/3423/35
TUMOUR FLARENeoplasms benign, malignant and unspecified (incl cysts and polyps)17/3421/3423/35
ANAEMIABlood and lymphatic system disorders11/3418/3415/35
DIARRHOEAGastrointestinal disorders14/3418/3416/35
PYREXIAGeneral disorders12/3415/3416/35
RASHSkin and subcutaneous tissue disorders9/348/3416/35
NAUSEAGastrointestinal disorders10/3415/3411/35
COUGHRespiratory, thoracic and mediastinal disorders10/3415/3412/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mgTotal
Mean64.0 ± 9.4663.3 ± 8.3163.7 ± 7.5663.6 ± 8.39
Age, Customized
Age, Customized(Participants)Lenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mgTotal
< 65 years16191752
≥ 65 years18161852
Sex: Female, Male
Sex: Female, Male(Participants)Lenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mgTotal
Female8131132
Male26222472
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lenalidomide 5 mgLenalidomide 10 mgLenalidomide 15 mgTotal
White31303394
Black or African American2428
Other0101
Unknown1001
09

Study locations

52 sites
  • UCSD Moores Cancer Center
    La Jolla, California 92093-0820, United States
  • Desert Hematology Oncology Medical Group, Inc.
    Rancho Mirage, California 92270, United States
  • Stanford University School of Medicine
    Stanford, California 94305-5821, United States
  • Cancer Center of Central Connecticut
    Southington, Connecticut 06489, United States
  • Cancer and Blood Disease Center
    Lecanto, Florida 34461, United States
  • Northwestern University Medical Center Division of Hematology Oncology
    Chicago, Illinois 60611-2927, United States
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • Indiana University Cancer Center
    Indianapolis, Indiana 46202-5149, United States
  • Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • Hackensack University Medical Center
    Hackensack, New Jersey 07601, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • Long Island Jewish Medical Center CLL Research and Treatment Program
    New Hyde Park, New York 11042, United States
  • Wake Forest University School of Medicine
    Winston-Salem, North Carolina 27104, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Drexel University, College of Medicine, Clinical Research Group
    Philadelphia, Pennsylvania 19102, United States
  • Cross Cancer Institute
    Edmonton, Alberta T6G 1Z2, Canada
  • Juravinski Cancer Centre
    Hamilton, Ontario L8V 5C2, Canada
  • CHU Sud
    Amiens, 80054, France
  • Hopital Avicenne
    Bobigny Cedex, 93009, France
  • CHU Grenoble
    Grenoble Cedex 09, 38043, France
  • Clinique Victor Hugo
    Le Mans, 72000, France
  • Institut Paoli Calmettes
    Marseille Cedex 9, 13273, France
  • CHU Montpellier - Hôpital Saint Eloi
    Montpellier Cedex 5, 34295, France
  • Hopital Emile Muller
    Mulhouse, 68000, France
  • Hopital Pitie Salpetriere
    Paris, 75651, France
  • CH Perpignan - Hopital Saint-Jean
    Perpignan, 66046, France
  • CHRU - Hopital du Haut Leveque
    Pessac, 33604, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite, 69310, France
  • Hopital Robert Debre
    REIMS cedex, 51092, France
  • CHU Rennes Hematology
    Rennes cedex, 35033, France
  • CHRU Hopital Brabois
    Vandoeuvre les Nancy, 54511, France
  • Charite -Universitätsmedizin Berlin
    Berlin, 13353, Germany
  • Universitatsklinikum Essen
    Essen, 45122, Germany
  • Ernst-Moritz-Arndt-Universität Greifswald
    Greifswald, 17487, Germany
  • Universitatsklinikum Schleswig Holstein
    Kiel, 24116, Germany
  • Klinikum der Universitat zu Koln
    Köln, 50924, Germany
  • University of Ulm Abteilung Innere Medizin III
    Ulm, 89081, Germany
  • Azienda Ospedaliera Universitaria San Martino
    Genova, 16132, Italy
  • Ematologia ed Immunologia, Azienda Ospedaliera "Vito Fazzi" di Lecce
    Lecce, 73100, Italy
  • I.R.C.C.S. Ospedale San Raffaele
    Milano, 20132, Italy
  • Istituto Europeo di Oncologia - IEO
    Milano, 20141, Italy
  • Universita degli Studi di Padova
    Padova, 35128, Italy
  • Universita' Degli Studi Di Perugia
    Perugia, 06100, Italy
  • Hospital Clinic Provincial de Barcelona
    Barcelona, 08036, Spain
  • Hospital Universitari Germans Trias i Pujol
    Barcelona, 08916, Spain
  • Karolinska Universitetssjukhuset
    Stockholm, 14186, Sweden
  • St James's Institute of Oncology
    Leeds, LS9 7TF, United Kingdom
  • St.Bartholomew's Hospital
    London, EC1M 6BQ, United Kingdom
  • King's College Hospital
    London, SE5 9RS, United Kingdom
  • The Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
  • Christie Hospital NHS Foundation Trust
    Manchester, M20 4BX, United Kingdom
10

References and documents

Publications

  • Wendtner CM, Hallek M, Fraser GA, Michallet AS, Hillmen P, Durig J, Kalaycio M, Gribben JG, Stilgenbauer S, Buhler A, Kipps TJ, Purse B, Zhang J, De Bedout S, Mei J, Chanan-Khan A. Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial. Leuk Lymphoma. 2016;57(6):1291-9. doi: 10.3109/10428194.2015.1128540. Epub 2016 Jan 14. PubMed 26763349 ↗
  • Buhler A, Wendtner CM, Kipps TJ, Rassenti L, Fraser GA, Michallet AS, Hillmen P, Durig J, Gregory SA, Kalaycio M, Aurran-Schleinitz T, Trentin L, Gribben JG, Chanan-Khan A, Purse B, Zhang J, De Bedout S, Mei J, Hallek M, Stilgenbauer S. Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J. 2016 Mar 11;6(3):e404. doi: 10.1038/bcj.2016.9. PubMed 26967821 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2009 to primary completion in Sep 2017, 94 months.

Results were first posted in Oct 2018, 1 year after primary completion.

Of 41 industry-sponsored phase 2 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 87. This study's 94 months is above that.

Counting every sponsor, half of 249 studies reached it within 73 months; a quarter within 41 and three quarters within 114.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2009
First posted
Aug 21, 2009
StartActual
Oct 19, 2009
Primary completionActual
Sep 5, 2017
CompletionActual
Sep 5, 2017
Results first posted
Oct 2, 2018
Last update
Oct 31, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 31, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT00963105
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Aug 21, 2009
Start date
Oct 19, 2009
Primary completion
Sep 5, 2017
Completion
Sep 5, 2017
Results posted
Oct 2, 2018
Last update
Oct 31, 2018

Study contacts

Jeffery Jones, M.D., MPH
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion